Cardiovascular
Page 1 • 8 itemsAccess global pharma market insights on cardiovascular drug development, clinical trials, regulatory approvals, and M&A activity. Stay ahead.
Edwards Lifesciences RESILIA Tissue Shows 10-Year Durability in Pivotal Aortic Valve Trial
Edwards Lifesciences announces 10-year COMMENCE trial results demonstrating long-term durability of RESILIA tissue for aortic valve replacement procedures.
AOP Health US Treats First Patient with Rapiblyk (Landiolol) in United States at Valley Hospital
AOP Health US achieves milestone with first Rapiblyk (landiolol) patient treatment at Valley Hospital, expanding critical care options nationwide.
Berlin Heals Reports Positive First-in-Human Results for Less Invasive Heart Failure Device in CMIC-III Study
Berlin Heals announces positive CMIC-III first-in-human study results showing improved heart function and quality of life with less invasive heart failure device.
Nectero Therapeutics Reports Positive Two-Year Safety Data for EAST System in Abdominal Aortic Aneurysm Trial
Nectero Therapeutics releases two-year safety and efficacy data from first-in-human trial of EAST System for small to medium abdominal aortic aneurysms.
Efemoral Medical's Bioresorbable Scaffold Achieves 97% Patency Rate in Peripheral Artery Disease Trial
Efemoral Medical reports exceptional 3-year results for its bioresorbable scaffold in femoropopliteal disease, achieving 97% primary patency and record-low stenosis rates.
Pulnovo Medical Secures $100 Million Investment from Medtronic for Pulmonary Hypertension Therapies
Pulnovo Medical raises $100M in oversubscribed funding led by Medtronic to advance breakthrough pulmonary hypertension and heart failure treatments.
FDA Approves Verapamil: Cardio-Med’s Extended-Release Formulation for Hypertension
The FDA has approved Cardio-Med’s extended-release formulation of Verapamil, offering a new option for managing hypertension effectively.
Medera's AAV-SERCA2a Gene Therapy Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Cardiomyopathy
Medera Inc. receives FDA Fast Track designation for AAV-SERCA2a gene therapy targeting cardiomyopathy in Duchenne muscular dystrophy patients.